Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer

Radiotherapy and Oncology

Volumn 122, Issue 1, 2017, Pages 93-98

  Lieng, Hester ^a,b   Pintilie, Melania ^a   Bayley, Andrew ^a,b   Berlin, Alejandro ^a,b   Bristow, Robert ^a,b   Chung, Peter ^a,b   Gospodarowicz, Mary ^a,b   Huang, Roger ^a,b,c   Ménard, Cynthia ^a,b,d   Warde, Padraig ^a,b   Catton, Charles ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WAIKATO HOSPITAL   (New Zealand)

^d NOTRE DAME HOSPITAL   (Canada)

Author keywords

Hypofractionation; Late toxicity; Outcomes; Prostate cancer; Radiotherapy

Indexed keywords

GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; CLINICAL TRIAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMAGE GUIDED INTENSITY MODULATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; IMAGE GUIDED RADIOTHERAPY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; DOSE HYPOFRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; TIME; TREATMENT OUTCOME;

EID: 85011026461     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.10.017     Document Type: Article

References (36)

1. [1] Vogelius, I.R., Bentzen, S.M., Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Phys 85 (2013), 89–94.
2. [2] Lee, W.R., Dignam, J.J., Amin, M.B., et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34 (2016), 2325–2332.
3. [3] Dearnaley, D., Syndikus, I., Mossop, H., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17 (2016), 1047–1060.
4. [4] Catton, C.N., Lukka, H., Julian, J.A., et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. J Clin Oncol, 34, 2016.
5. [5] Zemplenyi, A.T., Kalo, Z., Kovacs, G., et al. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl), 2016.
6. [6] Arcangeli, S., Strigari, L., Gomellini, S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1172–1178.
7. [7] Hoffman, K.E., Voong, K.R., Pugh, T.J., et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88 (2014), 1074–1084.
8. [8] Dearnaley, D., Syndikus, I., Sumo, G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13 (2012), 43–54.
9. [9] Pollack, A., Walker, G., Horwitz, E.M., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
10. [10] Aluwini, S., Pos, F., Schimmel, E., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17 (2016), 464–474.
11. [11] Martin, J.M., Rosewall, T., Bayley, A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69 (2007), 1084–1089.
12. [12] Vesprini, D., Sia, M., Lockwood, G., et al. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 81 (2011), e415–e421.
13. [13] Lukka, H., Warde, P., Pickles, T., et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 8 (2001), 1314–1322.
14. [14] Partin, A.W., Kattan, M.W., Subong, E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Jama 277 (1997), 1445–1451.
15. [15] Cox, J.D., Evolution and accomplishments of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 33 (1995), 747–754.
16. [16] Roach, M. 3rd, Hanks, G., Thames, H. Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006), 965–974.
17. [17] Arcangeli, G., Saracino, B., Gomellini, S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (2010), 11–18.
18. [18] Arcangeli, G., Fowler, J., Gomellini, S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79 (2011), 1013–1021.
19. [19] Dearnaley, D.P., Hypofractionated radiotherapy in prostate cancer. Lancet Oncol 16 (2015), 237–238.
20. [20] Aluwini, S., Pos, F., Schimmel, E., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.
21. [21] Boonstra, P.S., Taylor, J.M., Smolska-Ciszewska, B., et al. Alpha/beta (alpha/beta) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol, 89, 2016, 20150957.
22. [22] Williams, S.G., Taylor, J.M., Liu, N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007), 24–33.
23. [23] Proust-Lima, C., Taylor, J.M., Secher, S., et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79 (2011), 195–201.
24. [24] Fowler, J.F., The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44 (2005), 265–276.
25. [25] Cheung, M.R., Tucker, S.L., Dong, L., et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007), 1059–1065.
26. [26] Karlsdottir, A., Muren, L.P., Wentzel-Larsen, T., Dahl, O., Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 70 (2008), 1478–1486.
27. [27] Peeters, S.T., Heemsbergen, W.D., van Putten, W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005), 1019–1034.
28. [28] Patel, N., Faria, S., Cury, F., et al. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 86 (2013), 534–539.
29. [29] Rene, N., Faria, S., Cury, F., et al. Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 77 (2010), 805–810.
30. [30] Vanneste, B.G., Hoffmann, A.L., van Lin, E.N., Van De Voorde, L., Pinkawa, M., Lambin, P., Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiother Oncol 121 (2016), 118–123.
31. [31] Gomez-Iturriaga, A., Casquero, F., Urresola, A., et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial. Radiotherapy and oncology: journal of the European Society for Therapeutic. Radiol Oncol 119 (2016), 91–96.
32. [32] Sundahl, N., De Meerleer, G., Villeirs, G., et al. Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. Radiother Oncol 119 (2016), 398–404.
33. [33] Zietman, A.L., Bae, K., Slater, J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 28 (2010), 1106–1111.
34. [34] Dearnaley, D.P., Jovic, G., Syndikus, I., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15 (2014), 464–473.
35. [35] Dearnaley, D.P., Sydes, M.R., Graham, J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
36. [36] Kuban, D.A., Tucker, S.L., Dong, L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 67–74.